stock-detail (Novocure)

Oncology Corporate Profile

Brand Generic Indication
NovoTTF-100A System®medical deviceTheNovoTTF-100A System® is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically- or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

This company does not have any pipeline products

Recent News Headlines

There are no news items to display